Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk. / Johnsen, Søren P.; Rasmussen, Thomas B.; Falstie-Jensen, Anne Mette; Harboe, Louise; Stynes, Gillian; Dybro, Lars; Hansen, Morten L.; Brandes, Axel; Grove, Erik L.; Münster, Anna Marie.
I: Basic and Clinical Pharmacology and Toxicology, Bind 129, Nr. 3, 2021, s. 210-220.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Effectiveness and safety of oral anticoagulation treatment beyond 1 year after venous thromboembolism in patients at intermediate recurrence risk
AU - Johnsen, Søren P.
AU - Rasmussen, Thomas B.
AU - Falstie-Jensen, Anne Mette
AU - Harboe, Louise
AU - Stynes, Gillian
AU - Dybro, Lars
AU - Hansen, Morten L.
AU - Brandes, Axel
AU - Grove, Erik L.
AU - Münster, Anna Marie
N1 - Publisher Copyright: © 2021 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).
PY - 2021
Y1 - 2021
N2 - Effectiveness and safety of long-term anticoagulation treatment are uncertain in venous thromboembolism (VTE) patients at intermediate risk of recurrence. We examined the association between treatment beyond 1 year and outcomes in a Danish nationwide register-based study. VTE patients at intermediate risk of recurrence, that is, non-cancer patients with a first-time unprovoked VTE, who started oral anticoagulation treatment within 30 days and were alive 365 days after the index VTE were included and followed between 2007 and 2015. Exposure was extended (>365 days) or intermediate (91–365 days) treatment. Analyses were done using Cox regression on a propensity score weighted population. We included 18 609 patients with 7232 (38.9%) receiving extended treatment. Mean duration of follow-up was 2.6 years. Compared with intermediate treatment, treatment beyond 365 days was associated with a lower weighted risk of recurrent VTE (hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.49–0.65) and all-cause mortality (HR 0.81, 95% CI 0.72–0.90) and an increased risk of major bleeding (HR 1.87, 95% CI 1.58–2.22). In conclusion, extended anticoagulation treatment (predominantly warfarin) beyond 1 year was in real-life settings associated with a lower risk of recurrent VTE and all-cause mortality among VTE patients with an intermediate risk of recurrence. However, an increased bleeding risk should be considered.
AB - Effectiveness and safety of long-term anticoagulation treatment are uncertain in venous thromboembolism (VTE) patients at intermediate risk of recurrence. We examined the association between treatment beyond 1 year and outcomes in a Danish nationwide register-based study. VTE patients at intermediate risk of recurrence, that is, non-cancer patients with a first-time unprovoked VTE, who started oral anticoagulation treatment within 30 days and were alive 365 days after the index VTE were included and followed between 2007 and 2015. Exposure was extended (>365 days) or intermediate (91–365 days) treatment. Analyses were done using Cox regression on a propensity score weighted population. We included 18 609 patients with 7232 (38.9%) receiving extended treatment. Mean duration of follow-up was 2.6 years. Compared with intermediate treatment, treatment beyond 365 days was associated with a lower weighted risk of recurrent VTE (hazard ratio [HR] 0.56, 95% confidence interval [CI] 0.49–0.65) and all-cause mortality (HR 0.81, 95% CI 0.72–0.90) and an increased risk of major bleeding (HR 1.87, 95% CI 1.58–2.22). In conclusion, extended anticoagulation treatment (predominantly warfarin) beyond 1 year was in real-life settings associated with a lower risk of recurrent VTE and all-cause mortality among VTE patients with an intermediate risk of recurrence. However, an increased bleeding risk should be considered.
KW - epidemiology
KW - follow-up study
KW - oral anticoagulants
KW - venous thromboembolism
U2 - 10.1111/bcpt.13625
DO - 10.1111/bcpt.13625
M3 - Journal article
C2 - 34128322
AN - SCOPUS:85109024077
VL - 129
SP - 210
EP - 220
JO - Basic and Clinical Pharmacology and Toxicology
JF - Basic and Clinical Pharmacology and Toxicology
SN - 1742-7835
IS - 3
ER -
ID: 302817940